Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in A

The study met its primary objective of demonstrating statistically greater improvement from baseline in Eczema Area and Severity Index score at 16 weeks versus placeboPatients receiving KHK4083/AMG 451 showed statistically greater improvements in additional secondary efficacy endpoints versus placeboKHK4083/AMG 451...

Related Keywords

Germany ,Puerto Rico ,Japan ,Tokyo ,United States ,Canada ,America ,Michael Strapazon ,Stacey Minton ,Emma Guttman Yassky ,Trish Hawkins ,Asia Pacific ,Davidm Reese ,European Academy Of Dermatology ,Amgen ,Drug Administration ,Beigene Ltd ,Kyowa Kirin Us Research ,Virtual Congress On Oct ,Exchange Commission ,A Global Specialty Pharmaceutical Company ,Therapeutics Inc ,Icahn School Of Medicine At Mount Sinai ,Jolla Institute For Immunology ,Kyowa Kirin Co Ltd ,Department Of Dermatology ,Rd Division Of Kyowa Kirin ,Eczema Area ,Severity Index ,European Academy ,Virtual Congress ,Investigator Global Assessment ,Numerical Rating Scale ,System Chair ,Waldman Professor ,Icahn School ,Mount Sinai ,Inflammatory Skin Diseases ,Yoshifumi Torii ,Executive Officer ,Vice President ,Kyowa Kirin ,Kyowa Kirin Collaboration ,North America ,Five Prime Therapeutics ,Thousand Oaks ,